Lotus Pharmaceuticals Inc. announced the resignation of Mel Rothberg from the Company´s board of directors, effective April 21, 2008, for personal reasons. Mr. Rothberg served as a director since August 2006. Following his resignation, he will continue to serve as independent consultant to the Company, where he will provide advice and counsel on business development issues as they relate to Lotus´ corporate governance and pharmaceutical pipeline. Mr. Rothberg has extensive experience in senior management positions with pharmaceutical and medical device companies with operations worldwide.

Lotus Pharmaceuticals Inc. announced financial results for the fourth quarter and full year ended December 31, 2007. Total revenue in the fourth quarter was $19.2 million, an increase of 73% on year-over-year basis revenue of $11.1 million. This was primarily the result of strong performance associated with the Company´s continued efforts to develop its sales distribution channels. Net income for the fourth quarter of 2007 was $5.1 million, or $0.12 per diluted share, compared to loss of $0.1 million, or $0.00 per fully diluted share, in the fourth quarter of 2006. Adjusting net income for non-cash financing costs associated with its convertible notes, and a one-time forgiveness of income and value added taxes of $2.2 million, adjusted net income was $3.4 million, or $0.08 per fully diluted share, in the fourth quarter of 2007, up 68% from adjusted net income of $2.0 million, or $0.05 per fully diluted share, in the fourth quarter of 2006. For the full year 2007, total revenues were $56.9 million, up 57% from $36.2 million in 2006. Net income for 2007 was $11.2 million, or $0.26 per diluted share, compared to $4.1 million, or $0.10 per diluted share, in 2006. Adjusting net income for non-cash financing costs associated with its convertible notes, the previously mentioned one-time reversal of a sales allowance and a one-time forgiveness of income and value added taxes, adjusted net income was $8.5 million, or $0.19 per fully diluted share, in 2007, up 34% from adjusted net income of $6.3 million, or $0.16 per fully diluted share, in 2006.

Lotus Pharmaceuticals, Inc., Q4 2007 Earnings/Operating Results Call, Apr-17-2008